| Authors |
Fan Z, Guo G, Che X, Yang Y, Liu Y, Li L, Chang X, Han L, Cai X, Tang H. |
| MeSH |
Antiviral Agents / administration & dosage*
Antiviral Agents / adverse effects
COVID-19 / diagnosis
COVID-19 / therapy*
COVID-19 / virology
China
Combined Modality Therapy / adverse effects
Combined Modality Therapy / methods
Drugs, Chinese Herbal / administration & dosage*
Drugs, Chinese Herbal / adverse effects
Humans
Lung / diagnostic imaging
Nutritional Support
Oxygen / administration & dosage*
Oxygen / adverse effects
Randomized Controlled Trials as Topic
SARS-CoV-2 / isolation & purification
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome |
| 한글 키워드 |
코로나바이러스감염증-19, 효능, 연화청온, 메타분석, 무작위대조군연구, 안전성 |
| Abstract |
Background: : Coronavirus disease 2019 (COVID-19) is an emerging and rapidly evolving disease, with no recommended effective anti-coronavirus treatments. Traditional Chinese Medicine (TCM) has been widely used to treat COVID-19 in China, and the most used one is Lianhuaqingwen (LH). This study aimed to assess the efficacy and safety of LH combined with usual treatment vs usual treatment alone in treating mild or moderate COVID-19 by a meta-analysis of randomized controlled trials (RCTs).
Methods and analysis: : We systematically searched the Medline (OVID), Embase, the Cochrane Library, and 4 Chinese databases from inception to July 2020 to include the RCTs that evaluated the efficacy and safety of LH in combination with usual treatment vs usual treatment for mild or moderate COVID-19. A meta-analysis was performed to calculate the risk ratio (RR) and 95% confidence interval (CI) for binary outcomes and mean difference (MD) for continuous outcomes.
Results: : A total of 5 RCTs with 824 individuals with mild or moderate COVID 19 were included. Compared with the usual treatment alone, LH in combination with usual treatment significantly improved the overall clinical efficacy (RR = 2.39, 95% CI 1.61-3.55), increased the rate of recovery of chest computed tomographic manifestations (RR = 1.80, 95% CI 1.08-3.01), reduced the rate of conversion to severe cases (RR = 0.47, 95% CI 0.29-0.74), shorten the duration of fever (MD = -1.00, 95% CI -1.17 to -0.84). Moreover, LH in combination with usual treatment did not increase the occurrence of the adverse event compared to usual treatment alone.
Conclusion: : Our meta-analysis of RCTs indicated that LH in combination with usual treatment may improve the clinical efficacy in patients with mild or moderate COVID-19 without increasing adverse events. However, given the limitations and poor quality of included trials in this study, further large-sample RCTs or high-quality real-world studies are needed to confirm our conclusions.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. |
